Nelson Sun - 14 Feb 2025 Form 4 Insider Report for Aardvark Therapeutics, Inc. (AARD)

Reporting relationship: Chief Financial Officer
Issuer ticker: AARD
Reported as of: 14 Feb 2025
Net transaction value: +$160,000
SEC form: 4
Accepted by SEC: 19 Feb 2025, 16:30:49 UTC
Prior SEC filing: 12 Feb 2025
Next SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Nelson Sun

Key filing fact

Nelson Sun filed Form 4 for Aardvark Therapeutics, Inc. (AARD) on 19 Feb 2025.

Key facts

This page summarizes Nelson Sun's Form 4 filing for Aardvark Therapeutics, Inc. (AARD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2025, 16:30.

Change

Previous filing in this sequence was filed on 12 Feb 2025.
Current net transaction value: +$160,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AARD transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +7,001
Change %: +8.5%
Price
Shares after: 89,484
Date: 14 Feb 2025
Ownership: Direct
Footnotes: F1

AARD transaction

Common Stock

Purchase

Transaction value: $160,000
Shares: +10,000
Change %: +11%
Price: $16.00
Shares after: 99,484
Date: 14 Feb 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AARD transaction Derivative

Series C Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -59,332
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 14 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,001
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date.